Premium
Evaluation of recombinant sporozoite antigen SPAG‐1 as a vaccine candidate against Theileria annulata by the use of different delivery systems
Author(s) -
Boulter Nicola,
Brown Duncan,
Wilkie Gwen,
Williamson Susanna,
Kirvar Erol,
Knight Pamela,
Glass Elizabeth,
Campbell John,
Morzaria Subhash,
Nene Vish,
Musoke Anthony,
D'oliveira Christine,
Gubbels MarcJan,
Jongejan Frans,
Hall Roger
Publication year - 1999
Publication title -
tropical medicine and international health
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.056
H-Index - 114
eISSN - 1365-3156
pISSN - 1360-2276
DOI - 10.1046/j.1365-3156.1999.00453.x
Subject(s) - adjuvant , antigen , virology , recombinant dna , vaccination , protein subunit , biology , immunology , biochemistry , gene
Summary The major sporozoite surface antigen of Theileria annulata (SPAG‐1) is a candidate for inclusion in a subunit vaccine. In this paper we summarize the results of 4 vaccination experiments using recombinant SPAG‐1 expressed in different systems and presented in different adjuvants. The antigen has been presented as either a C terminal 108 amino acid peptide (called SR1) expressed as both β‐galactosidase and hepatitis B core antigen fusions or as a full‐length form expressed as a GST fusion with an N terminal His6 tag. We used different adjuvants, namely Freund's, saponin, ISCOMs and a proprietary adjuvant supplied by SmithKline Beecham, which we call SKBA. The data point to the conclusion that SPAG‐1 can elicit partial protection and is therefore suitable for inclusion in an eventual multicomponent subunit vaccine.